Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles
摘要:
We have previously reported the discovery and initial SAR of the [1,7]naphthyridine-3-carbonitriles and quinoline-3-carbonitriles as Tumor Progression Loci-2 (Tp12) kinase inhibitors. In this paper, we report new SAR efforts which have led to the identification of 4-alkylamino-[1,7]naphthyridine-3-carbonitriles. These compounds show good in vitro and in vivo activity against Tp12 and improved pharmacokinetic properties. In addition they are highly selective for Tp12 kinase over other kinases, for example, EGFR, MEK, MK2, and p38. Lead compound 4-cycloheptylamino-6-[(pyridin-3-ylmethyl)-amino]-[1,7]naphthyridine-3-carbonit-rile (30) was efficacious in a rat model of LPS-induced TNF-alpha production. (C) 2007 Elsevier Ltd. All rights reserved.
Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles
摘要:
We have previously reported the discovery and initial SAR of the [1,7]naphthyridine-3-carbonitriles and quinoline-3-carbonitriles as Tumor Progression Loci-2 (Tp12) kinase inhibitors. In this paper, we report new SAR efforts which have led to the identification of 4-alkylamino-[1,7]naphthyridine-3-carbonitriles. These compounds show good in vitro and in vivo activity against Tp12 and improved pharmacokinetic properties. In addition they are highly selective for Tp12 kinase over other kinases, for example, EGFR, MEK, MK2, and p38. Lead compound 4-cycloheptylamino-6-[(pyridin-3-ylmethyl)-amino]-[1,7]naphthyridine-3-carbonit-rile (30) was efficacious in a rat model of LPS-induced TNF-alpha production. (C) 2007 Elsevier Ltd. All rights reserved.
3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same
申请人:Green Jeffrey Neal
公开号:US20060264460A1
公开(公告)日:2006-11-23
The present invention provides compounds of formula (I):
and pharmaceutically acceptable salts thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, m and n are defined as described herein. The invention also provides methods of making the compounds of formula (I), and methods of treating inflammatory diseases, such as rheumatoid arthritis, in a mammal comprising administering a therapeutically effective amount of a compound of formula (I) to the mammal.
Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles
作者:Neelu Kaila、Neal Green、Huan-Qiu Li、Yonghan Hu、Kristin Janz、Lori Krim Gavrin、Jennifer Thomason、Steve Tam、Dennis Powell、John Cuozzo、J. Perry Hall、Jean-Baptiste Telliez、Sang Hsu、Cheryl Nickerson-Nutter、Qin Wang、Lih-Ling Lin
DOI:10.1016/j.bmc.2007.06.054
日期:2007.10
We have previously reported the discovery and initial SAR of the [1,7]naphthyridine-3-carbonitriles and quinoline-3-carbonitriles as Tumor Progression Loci-2 (Tp12) kinase inhibitors. In this paper, we report new SAR efforts which have led to the identification of 4-alkylamino-[1,7]naphthyridine-3-carbonitriles. These compounds show good in vitro and in vivo activity against Tp12 and improved pharmacokinetic properties. In addition they are highly selective for Tp12 kinase over other kinases, for example, EGFR, MEK, MK2, and p38. Lead compound 4-cycloheptylamino-6-[(pyridin-3-ylmethyl)-amino]-[1,7]naphthyridine-3-carbonit-rile (30) was efficacious in a rat model of LPS-induced TNF-alpha production. (C) 2007 Elsevier Ltd. All rights reserved.